Literature DB >> 9708453

Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment.

J Sandoval1, J Gaspar, T Pulido, E Bautista, M L Martínez-Guerra, M Zeballos, A Palomar, A Gómez.   

Abstract

OBJECTIVES: We sought to investigate the acute hemodynamic effects of graded balloon dilation atrial septostomy (BDAS) and to define the long-term impact of this procedure on New York Heart Association functional class and survival in adult patients with primary pulmonary hypertension (PPH).
BACKGROUND: Current treatment strategies for patients with severe and refractory PPH are limited by either technical difficulties and high mortality or cost.
METHODS: We studied 15 patients with severe PPH. BDAS was successfully performed in all patients by crossing the interatrial septum with a Brockenbrough needle, followed by progressive dilation of the orifice with a Mansfield balloon in a hemodynamically controlled, step-by-step manner.
RESULTS: BDAS caused an immediate significant fall in right ventricular end-diastolic pressure and in systemic arterial oxygen saturation and an increase in cardiac index. One patient died, and 14 survived the procedure and significantly improved their mean functional class (from 3.57 +/- 0.6 to 2.07 +/- 0.3 [mean +/- SD], p < 0.001). Exercise endurance (6-min test) also improved from 107 +/- 127 to 217 +/- 108 m (p < 0.001). Because of spontaneous closure, BDAS was repeated in four patients. The survival rate among patients who survived the procedure was 92% at 1, 2 and 3 years, which is better than that for historical control PPH patients (73%, 59% and 52%, respectively).
CONCLUSIONS: With careful monitoring, BDAS is a safe and useful palliative treatment for selected patients with severe PPH.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9708453     DOI: 10.1016/s0735-1097(98)00238-1

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  45 in total

Review 1.  Pulmonary arterial hypertension: new ideas and perspectives.

Authors:  N Galiè; A Torbicki
Journal:  Heart       Date:  2001-04       Impact factor: 5.994

2.  Recommendations on the management of pulmonary hypertension in clinical practice.

Authors: 
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

Review 3.  [Consensus recommendations of the Pulmonary Arterial Hypertension Study Group of the Austrian Society of Lung Diseases and Tuberculosis].

Authors:  Rolf Ziesche
Journal:  Wien Klin Wochenschr       Date:  2003-05-30       Impact factor: 1.704

4.  Atrial septostomy for pulmonary arterial hypertension.

Authors:  R J Allcock; J J O'Sullivan; P A Corris
Journal:  Heart       Date:  2003-11       Impact factor: 5.994

Review 5.  [Extracardiac causes of right ventricular insufficiency].

Authors:  B Maisch; M Christ
Journal:  Internist (Berl)       Date:  2004-10       Impact factor: 0.743

6.  Use of Amplatzer fenestrated atrial septal defect device in a child with familial pulmonary hypertension.

Authors:  Alain Fraisse; Philippe Chetaille; Zahid Amin; Francis Rouault; Marc Humbert
Journal:  Pediatr Cardiol       Date:  2006-11-16       Impact factor: 1.655

Review 7.  Pulmonary arterial hypertension: classification, diagnosis and contemporary management.

Authors:  D J Fox; R S Khattar
Journal:  Postgrad Med J       Date:  2006-11       Impact factor: 2.401

Review 8.  Congenital diaphragmatic hernia and associated cardiovascular malformations: type, frequency, and impact on management.

Authors:  Angela E Lin; Barbara R Pober; Ian Adatia
Journal:  Am J Med Genet C Semin Med Genet       Date:  2007-05-15       Impact factor: 3.908

Review 9.  Severe paediatric pulmonary hypertension: new management strategies.

Authors:  A Rashid; D Ivy
Journal:  Arch Dis Child       Date:  2005-01       Impact factor: 3.791

Review 10.  Treatment of pulmonary arterial hypertension in children.

Authors:  Heiner Latus; Tammo Delhaas; Dietmar Schranz; Christian Apitz
Journal:  Nat Rev Cardiol       Date:  2015-02-03       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.